HIGHLIGHTS
- who: Yan Yan and colleagues from the Wuxi Affiliated Clinical Academy of Nantong University, Wuxi, China have published the paper: CCL28 Enhances HSV-2 gB-Specific Th1-Polarized Immune Responses against Lethal Vaginal Challenge in Mice, in the Journal: Vaccines 2022, x of /2022/
- what: Findings in this study provide a basis for the development of CCL28-adjuvant vaccines viral mucosal infections. Given that CCL28 as a molecular adjuvant at a high dose demonstrated toxicities, as well as ineffective antiviral immunoprotective effects , in the current study, the authors investigated whether and how a low dose . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.